Gut microbial indole-3-pyruvic acid augments anti-breast cancer efficacy of PD-1 inhibitor
IPyA as a key player in the modulation of positive tumor immune microenvironment, pioneering novel strategy that employs the power of gut microbiota in ICIs treatment.